person · Reporting owner
Brewer Joanna Elizabeth
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptimmune Therapeutics PLCADAP · Entity 9824 | Chief Scientific Officer | February 20, 2025 | February 20, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptimmune Therapeutics PLC
Report date February 20, 2025 · Filed February 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.10 · Expires 2035-02-20 | Direct | 1,612,032 |
Reported balance
After 2025-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-20 · Grant · Acquired 1,612,032 · Balance 1,612,032 F1: The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2: Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029. |
| Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2035-02-20 | Direct | 1,074,696 |
Reported balance
After 2025-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-20 · Grant · Acquired 1,074,696 · Balance 1,074,696 F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4: Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F2: Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029.
F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F4: Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2025 Filed Feb 20, 2025 17:34 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,074,696 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015745 · tm257186-5_4seq1.xml · derivative · entry 2 Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,074,696 Underlying: Ordinary Shares · 1,074,696 shares Expires 2035-02-20 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029. Read SEC document |
| February 20, 2025 Filed Feb 20, 2025 17:34 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,612,032 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001104659-25-015745 · tm257186-5_4seq1.xml · derivative · entry 1 Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,612,032 Underlying: Ordinary Shares · 1,612,032 shares Expires 2035-02-20 F1 · derivative.exercise_price: The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029. Read SEC document |
| January 15, 2024 Filed Jan 17, 2024 17:02 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 565,416 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004527 · tm243270-9_4seq1.xml · derivative · entry 2 Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,416 Underlying: Ordinary Shares · 565,416 shares Expires 2034-01-15 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028. Read SEC document |
| January 15, 2024 Filed Jan 17, 2024 17:02 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 2,544,432 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001104659-24-004527 · tm243270-9_4seq1.xml · derivative · entry 1 Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,544,432 Underlying: Ordinary Shares · 2,544,432 shares Expires 2034-01-15 F1 · derivative.exercise_price: The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028. Read SEC document |
| January 17, 2023 Filed Jan 17, 2023 21:05 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 135,480 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004374 · tm231655-14_4seq1.xml · derivative · entry 3 Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,480 Underlying: Ordinary Shares · 135,480 shares Expires 2033-01-17 F5 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| January 17, 2023 Filed Jan 17, 2023 21:05 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 314,256 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004374 · tm231655-14_4seq1.xml · derivative · entry 2 Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,256 Underlying: Ordinary Shares · 314,256 shares Expires 2033-01-17 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027. Read SEC document |
| January 17, 2023 Filed Jan 17, 2023 21:05 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,407,072 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001104659-23-004374 · tm231655-14_4seq1.xml · derivative · entry 1 Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,407,072 Underlying: Ordinary Shares · 1,407,072 shares Expires 2033-01-17 F1 · derivative.exercise_price: The exercise price was converted from GBP0.26 based on an exchange rate of U.S.$1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027. Read SEC document |
| May 04, 2022 Filed May 4, 2022 21:03 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 223,512 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-056007 · tm2214456-2_4seq1.xml · derivative · entry 2 Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,512 Underlying: Ordinary Shares · 223,512 shares Expires 2032-05-04 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.2513 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 55,878 Ordinary Shares on May 4, 2023 and will be exercisable as to the remainder in annual installments of 55,878 Ordinary Shares on the fourth of each May from May 4, 2024 through May 4, 2026. Read SEC document |
| May 04, 2022 Filed May 4, 2022 21:03 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 333,792 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001104659-22-056007 · tm2214456-2_4seq1.xml · derivative · entry 1 Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,792 Underlying: Ordinary Shares · 333,792 shares Expires 2032-05-04 F1 · derivative.exercise_price: The exercise price was converted from GBP0.24 based on an exchange rate of U.S.$1.2513 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 83,448 Ordinary Shares on May 4, 2023 and will be exercisable as to the remainder in monthly installments of 6,954 Ordinary Shares on the fourth of each month from June 4, 2023 through May 4, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.